DURECT Corporation (DRRX)

Market Cap	24.80M
Revenue (ttm)	8.59M
Net Income (ttm)	-17.07M
Shares Out	31.04M
EPS (ttm)	-0.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,377
Open	0.800
Previous Close	0.810
Day's Range	0.770 - 0.800
52-Week Range	0.700 - 1.880
Beta	0.91
Analysts	Buy
Price Target	5.00 (+525.78%)
Earnings Date	Mar 26, 2025

About DRRX

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company’s lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osm...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Sep 28, 2000
• Employees: 58
• Stock Exchange: NASDAQ
• Ticker Symbol: DRRX
• Website: https://www.durect.com

Financial Performance

In 2023, DURECT's revenue was $8.55 million, a decrease of -55.67% compared to the previous year's $19.28 million. Losses were -$27.62 million, -21.82% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for DRRX stock is "Buy." The 12-month stock price forecast is $5.0, which is an increase of 525.78% from the latest price.

Price Target

$5.0

(525.78% upside)

Analyst Consensus: Buy